Home / Business and Economy / Nestle Bets on AI for Weight-Loss Drug Side Effects
Nestle Bets on AI for Weight-Loss Drug Side Effects
17 Aug
Summary
- Nestle uses AI to develop products for GLP-1 drug users.
- Products aim to mitigate side effects like muscle loss.
- AI analyzes research to identify key nutrient combinations.
Nestle is proactively addressing the rise of GLP-1 weight-loss drugs, turning a potential threat into a significant business opportunity. The company is employing artificial intelligence and advanced nutritional science to create products tailored for the millions of consumers using medications like Ozempic and Wegovy.
These specialized products aim to mitigate common side effects associated with rapid weight loss, including muscle mass reduction and facial fat loss. Nestle's Chief Technology Officer, Stefan Palzer, highlighted the use of AI to analyze extensive clinical research, identify critical nutrient combinations, and accelerate product development.
The company is integrating ingredients like collagen protein into its Vital Proteins brand to support skin, hair, and nail health. Nestle has also patented proprietary ingredient combinations designed to help manage increased hunger post-treatment, with products like Boost Advanced Nutrition Shake already launched in the U.S.
